Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AlvotechHAM:Z45 +8.06%48 EBITDA Margin % is 49.19% as of Mar. 2026. GuruFocus rates HAM:Z45 with a GF Score™ of 48/100 and a GF Value™ of €16.65 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 961 Drug Manufacturers companies, Alvotech ranks better than 93.86% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Alvotech's EBITDA for the
three
months ended in Mar. 2026 was €45.0 Mil. Alvotech's Revenue for the
three
months ended in Mar. 2026 was €91.6 Mil. Therefore, Alvotech's EBITDA margin for the quarter that ended in Mar. 2026 was 49.19%.
Alvotech (HAM:Z45) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Alvotech EBITDA Margin % Related Terms
Alvotech EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Alvotech's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:Z45 vs PAHC, COLL, XERS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Alvotech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alvotech EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alvotech's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Alvotech's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alvotech (HAM:Z45) has a EBITDA Margin % of 49.19% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Alvotech and its competitors. According to the industry distribution chart, Alvotech ranks #59 out of 961 companies in the Drug Manufacturers industry, placing it in the top 6.1%.
Is Alvotech's EBITDA Margin % too high?
Alvotech's current EBITDA Margin % is 49.19%. The Drug Manufacturers industry median EBITDA Margin % is 12.49. Alvotech's value of 49.19% is 293.8% above this industry median. Based on the distribution chart, Alvotech ranks #59 out of 961 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Alvotech has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Alvotech's EBITDA Margin % compare to PAHC and COLL?
According to the Drug Manufacturers industry distribution chart, Alvotech ranks #59 out of 961 companies for EBITDA Margin %. This places Alvotech in the top 6% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.49. Alvotech's value of 49.19% is 293.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alvotech's current EBITDA Margin % of 49.19% is 293.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Alvotech and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alvotech's current EBITDA Margin % is 49.19%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alvotech stock overvalued right now?
Based on GuruFocus' analysis, Alvotech (HAM:Z45) is currently considered Possible Value Trap. The stock's GF Value™ is €16.65, compared to a current price of €2.95 — trading 82.3% below its estimated fair value. The current EBITDA Margin % is 49.19% and 293.8% above the Drug Manufacturers industry median of 12.49. Alvotech's overall GF Score™ is 48/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Alvotech (HAM:Z45), the current EBITDA Margin % is 49.19% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alvotech (HAM:Z45) Overvalued in 2026?
Based on GuruFocus' analysis, Alvotech stock appears to be undervalued.
The current stock price of €2.95 is trading 82.3% below its estimated GF Value™ of €16.65.
GuruFocus considers Alvotech to be Possible Value Trap.
Key valuation signals for HAM:Z45:
EBITDA Margin %: 49.19%
GF Value™: €16.65 vs. price of €2.95 (82.3% below fair value)
Industry Position: 293.8% above the Drug Manufacturers median (#59 of 961)
No single metric tells the full story. See the HAM:Z45 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
48GF Score
Get the complete analysis for HAM:Z45
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:Z45 has been successfully added to your 
